Zentalis director granted 57,100 RSUs

Myers Scott Dunseth reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Myers Scott Dunseth reported acquisition or exercise transactions in this Form 4 filing.

Zentalis Pharmaceuticals director Scott Dunseth Myers received a grant of 57,100 restricted stock units (RSUs). The award was made at no cash cost and increases his direct holdings to 395,895 shares of common stock. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to his continued board service.

Insider Trade Summary

Grant/Award: 57,100 shares

Grant/Award 1 txn

Insider Myers Scott Dunseth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	57,100	$0.00	$0.00

Holdings After Transaction: Common Stock — 395,895 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Key Figures

RSU grant size: 57,100 units Grant price: $0.00 per share Holdings after transaction: 395,895 shares +1 more

4 metrics

RSU grant size 57,100 units Restricted stock units granted to director on June 16, 2026

Grant price $0.00 per share RSUs granted at no cash cost to the director

Holdings after transaction 395,895 shares Total direct Zentalis common stock holdings after RSU grant

RSU vesting date June 16, 2027 Vests on earlier of this date or next annual stockholder meeting

Key Terms

restricted stock units, Non-Employee Director Compensation Program, contingent right, vesting

4 terms

restricted stock units financial

"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Program financial

"restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"

contingent right financial

"each of which represents a contingent right to receive one share of common stock"

vesting financial

"which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zentalis (ZNTL) director Scott Dunseth Myers report on this Form 4?

Scott Dunseth Myers reported receiving 57,100 restricted stock units in Zentalis Pharmaceuticals common stock. These RSUs were granted as director compensation and increase his direct holdings to 395,895 shares after the transaction, according to the Form 4 details and accompanying footnote.

How many Zentalis (ZNTL) shares does Scott Dunseth Myers hold after this grant?

After the reported grant, Scott Dunseth Myers directly holds 395,895 shares of Zentalis common stock. This total includes the newly awarded 57,100 restricted stock units, which each represent a contingent right to receive one share upon vesting, as disclosed.

What are the vesting terms of Scott Dunseth Myers’ RSU grant at Zentalis (ZNTL)?

The 57,100 restricted stock units vest on the earlier of June 16, 2027 or the next annual meeting of Zentalis stockholders. Vesting is conditioned on Myers’ continued service on the company’s Board of Directors through the applicable vesting date, per the footnote.

Was Scott Dunseth Myers’ Zentalis (ZNTL) RSU grant an open-market purchase?

No, the Form 4 shows the transaction code "A," indicating a grant or award, not an open-market purchase. The RSUs were granted at a price of $0.00 per share as part of the company’s Non-Employee Director Compensation Program, rather than bought in the market.

What does each Zentalis (ZNTL) RSU granted to Scott Dunseth Myers represent?

Each restricted stock unit represents a contingent right to receive one share of Zentalis common stock. The units convert into shares only upon vesting, which occurs on the earlier of June 16, 2027 or the next annual stockholder meeting, assuming continued board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Myers Scott Dunseth

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		A		57,100(1)	A	$0	395,895	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James B. Bucher, attorney-in-fact for Scott Myers	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)